BioSpace News Archive

Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers

The identification of multiple genomic markers that are linked to specific mental health diseases is beginning to improve treatments and enable precision psychiatry.

Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.

Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.

Cognition Therapeutics will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for Alzheimer’s disease and other neurodegenerative disorders.

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2021 financial and operating results on Tuesday, March 15, 2022 before the market opens.

Sensei Biotherapeutics, Inc. today reported financial results for 2021 and provided recent corporate updates.

Dyne Therapeutics, Inc. today reported financial results for the fourth quarter and full year 2021 and recent business highlights.

Inari Medical, Inc. today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock.

PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Cleveland Clinic today announced a five-year strategic collaboration that will focus on leveraging PathAI’s quantitative pathology algorithms both to conduct new translational research and for use as clinical diagnostics in multiple disease areas.